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On tissue engineering field the research about skin substitutes represents historically the 
most promising approach to heal acute and chronic skin wounds, reducing requirements for 
donor skin autografts. Aim of this chapter is to made the state of art of the most important 
skin substitutes and to resume the principal tissue engineering techniques for its in vitro 
reconstruction. In the first part we will pay the attention to the description of the evolutive 
course of skin substitutes, stressing the main steps happened thanks to the important inputs 
coming from biotechnologies progresses and clinical practice. Since then the research in 
bioengineering skin, moved by clinical pressing of reconstructive and burn surgery, made 
progresses trying to develop cutaneous substitutes very similar to native skin by a morpho-
functional point of view. So it has been possible, starting from a 2X2 cm skin human biopsy, 
to realize completely autologous cutaneous substitutes not only composed of two many 
structures of skin, dermis and epidermis, but containing also other important components: 
microvascular network, micro nervous network, skin immonocompetent system and 
melanocyte system. The final goal is to develop effective and easy handling skin substitutes 
that could be reproduce human skin anatomy and physiology, introducing new advantages 
linked to successful grafting and then to satisfactory clinical results by functional and 
aesthetic point of view.  
 
1. Introduction 
Tissue Engineering (TE) is "an interdisciplinary field that applies the principles of 
engineering and life sciences toward the development of biological substitutes that restore, 
maintain, or improve tissue function or a whole organ". Tissue engineering has also been 
defined as "understanding the principles of tissue growth, and applying this to produce 
functional replacement tissue for clinical use."  
Powerful recent developments in the multidisciplinary field of tissue engineering have 
yielded a novel set of tissue replacement parts and implementation strategies. Scientific 
advances in biomaterials, stem cells, growth and differentiation factors, and biomimetic 
environments have created unique opportunities to fabricate tissues in the laboratory from 
combinations of engineered extracellular matrices ("scaffolds"), cells, and biologically active 
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molecules. Among the major challenges now facing tissue engineering there is the need for 
more complex functionality with biomechanical stability in laboratory-grown tissues 
destined for transplantation.  
Thus, the scientific and medical communities are working together to develop engineered 
tissues and regenerative approaches utilizing various combinations of stem and progenitor 
cells, biomaterials, growth factors, and gene therapy. However, after three decades, the 
potential to provide tissues and organs to millions of patients suffering from trauma, 
congenital defects, and chronic diseases has yet to be fully accomplished.  
On the whole, tissue engineering appears to be the new frontier of medicine for its impact 
on regenerative and reconstructive procedures in humans. In fact, its ultimate goal is to 
develop powerful new therapies, namely “biological substitutes”, for structural and 
functional disorders that have been proven to be difficult or impossible to tackle 
successfully with the current approaches of interventional medicine. In addition, providing 
“cell-to-tissue replacement parts” of the human body it can ultimately afford the 
irremediable shortage of transplantable organs. 
Despite the rapid advancement of state of the art medically driven technologies, numerous 
challenges still exist for translating technology to the clinic including long and often 
undefined regulatory approval pathways, high translational costs, potential safety 
appropriate risk/benefit and cost/benefit ratios, and appropriate matching of technology 
and application. The latter may be one of the most difficult tasks faced by the biomedical 
engineer. Although development of general platform technologies can lead to major 
breakthroughs across multiple disciplines, conventional wisdom suggests rapid clinical 
translation and requires a systematic approach that involves first identifying and 
understanding a problem followed by engineering a focused solution. As technology 
rapidly advances, the bioengineer have more tools at their disposal than ever before, yet 
only if they are able to select the right tools and technologies, for society benefit. 
Tissue engineered substitutes should have some essential characteristics which include: 
being easy to handle and apply to the injured site; provide vital barrier function with 
appropriate water flux; be readily adherent; have appropriate physical and mechanical 
properties; undergo controlled degradation; be sterile, non-toxic, non-antigenic; and evoke 
none or minimal inflammatory reactivity. Additionally, they should incorporate into the 
host with minimal scarring and pain and facilitate angiogenesis, while still being cost-
effective.  
The ability to create thick tissues is a major tissue engineering challenge, requiring the 
development of a suitable vascular supply. Current trends are seeing the utilization of cells 
seeded into hybrid matrix/scaffold systems to create in vitro vascular analogues. 
Approaches that aim to create vasculature in vitro include the use of biological extracellular 
matrices, co-culture of cells, incorporation of growth factors, culture in dynamic bioreactor 
environments, and combinations of these. Of particular interest are those approaches that 
aim to create bioengineered tissues in vitro that can be readily connected to the host's 
vasculature following implantation in order to maintain cell viability. A major consideration 
when developing a tissue engineering strategy for promoting repair and regeneration is to 
identify suitable sources of cells and mechanisms by which they can function and interact 
properly. These cells would also have to be abundant enough to be able to carry out the 
regeneration process completely.  
Another obstacle to the large scale clinical application of cell therapy using conventional 
procedure is the extremely high cost of the treatment. The economic limit is due to the high 
cost of the actual manual operations for ex vivo cell expansion and differentiation in respect 
of the international regulations (Good laboratory and manufacture practices, GLP, GMP or 
Food and Drug Administration, FDA) that control the trading of clinical products.  
Therefore there is a diffuse and pressing necessity to develop new methods and culture 
techniques that are able to control the cell micro-environment during both cell expansion 
and differentiation leading to repeatable clinical grade batches, operating in safety 
conditions and at low costs. This last point is often ignored but it is fundamental to make the 
clinical progresses available to everybody and not only to few people. 
 
2. Anatomy of the skin  
The skin is the largest organ of the body in vertebrates and is composed of the epidermis 
and dermis with a complex nerve and blood supply (Fig. 1). A third layer the hypodermis, is 
composed mainly of fat and a layer of loose connective tissue. These three layers play an 
important role in protecting the body from any mechanical damage such as wounding.  
I. The epidermis is thin and highly cellular, composed mainly of keratinocytes and in the 
lower epidermal layers, melanocytes, for pigmentation. It does, however, have 
sufficient thickness to provide vital barrier function. Mammalian epidermis and its 
appendages (hair, nail, sweat and sebaceous glands) maintain homeostasis by constant 
recycling of the basal cell layer.  
II. The dermis situated directly below the epidermis, constitutes the bulk of the skin and 
is composed of collagen with some elastin and glycosaminoglycans (GAG’s). 
Hemidesmosomal structure are the main components of the basement membrane that 
mechanically stabilizes the interaction between epidermis and dermis. Basement 
membrane is an extremely complex and dynamic structure, which is responsible of the 
tight junction of the upper epidermis and underlying connective tissue. The dermis is a 
thicker tissue made essentially of a loose array of fibroblasts (mesenchymal cells) and 
vasculature (endothelial cells) forming an approximately 2-5 mm thick connective 
tissue sustaining the overlaid epidermis which is separated from the dermis by a 20 
nm thick multilayered membrane: basement membrane. The dermal matrix, which 
provides considerable strength to skin by virtue of the arrangement of collagen fibers, 
has specialized components and structures. Collagenous mesh work is interwoven 
with varying contents of elastin fibers, proteoglycons (GAG being predominantly 
hyaluronic acid and dermatan sulfate with some chondroitin-6-sulphate and heparin 
sulphate), fibronectin and other components. (Metcalfe and Ferguson 2007) 
III. The hypodermis, the final layer, contains adipose tissue that is well vascularised 
and contributes to both the thermoregulatory and mechanical properties of the 
skin. 
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 Fig. 1. Anatomy of the skin: dermis with fibroblasts and epidermis with keratinocytes 
 
Skin is also composed of a series of appendages known as anexa, such as hair follicles, sweat 
glands and sebaceous glands generally embedded in the dermis. Because the skin serves as 
a protective barrier against the outside world, any break in it must be rapidly and efficiently 
amended. (Jennings RW and  Hung TK 1982). The physiologic mechanism that coordinates 
the ordered repair of cutaneous tissues is generally referred to as wound healing and it 
consists in a well orchestrated series of temporary overlapping actions involving different 
cell and biochemical types. The process of wound healing involves interaction of a variety of 
different cell types and matrix components (R.A.F. Clark and P.M. Henson 1988). Different 
types of cells respond to environmental signals in a specific manner in order to carry out 
their genetic program of proliferation, differentiation and function. Cells synthesize 
different proteins necessary for their proliferation and migration, all of which are controlled 
in a phased manner (Zavan and Abatangelo 2004). Different phases are inflammation, 
granulation tissue formation, re-epithelialization, matrix production and remodelling Thus, 
each layer of skin plays its own pivotal role to play in the normal function of the skin, which 
otherwise can lead to several skin disorders. Healing of injured tissues involves both 
regeneration of the epidermis and repair of the dermis resulting in a scar tissue (M Calvin 
1998). 
 
dermis 
epidermis 
3. Wound Healing  
Wounds can arise either acutely from traumas such as burns, derive from surgical 
treatments such as skin graft harvesting or melanoma excision or also in a chronic fashion 
related to patho-physiological phenomena like insufficient vascularization, as in pressure 
wounds or diabetic foot ulcers. The underlying principles behind the use of skin substitutes 
to improve wound healing are valid for extensive wounds that cannot heal spontaneously 
because they are deep and affect a high percentage of the total body surface or for smaller 
wounds that cannot heal because of underlying factors (Auger and Lacroix 2009). 
The normal acute wound healing process takes place in 4 steps (FIG.2): 
1) hemostasis, 
2) inflammation,  
3) proliferation,  
4) remodeling. 
 
 Fig. 2. Time table of wound healing process 
 
Hemostasis 
Unless there is severe arterial hemorrhage, hemostasis spontaneously begins immediately 
after the injury. It involves platelet aggregation, fibrin clot formation and activation of the 
coagulation pathways. Since the first aspects of wound treatment involve cleaning and 
debriding the wound, skin substitutes are rarely, if ever, used for hemostasis. However, it 
should be noted that chitosan dressings have been demonstrated to efficiently improve 
hemostasis compared to standard dressings, even with significant arterial hemorrhage 
[Garner and Brown R 2002] 
Inflammation 
Inflammation takes place 1–4 days after wounding. It involves the migration of neutrophils 
into the wound site, shortly followed by macrophages and later by lymphocytes. The fibrin 
clot matrix   provides a three-dimensional initial scaffold through which immune cells will 
initially migrate to the wound and secrete a host of signaling molecules that will act as 
chemoattractants and growth factors. Platelets will produce factors such as platelet-derived 
growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor- (TGF-
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), transforming growth factor-  (TGF- ) and vascular endothelial growth factor (VEGF). 
[Werner and Grose 2003; Spiekstra et al. 2007].  
Proliferation 
Factors secreted during inflammation will trigger and drive the proliferation stage, which 
normally takes place between days 4 and 21 following wounding. During that stage, 
fibroblasts are stimulated by fibroblast growth factor (FGF) and PDGF to invade the wound 
site, and will produce  xtracellular matrix (ECM) components, such as collagen, elastin and 
glycosaminoglycans, to generate the granulation tissue. Fibroblasts secrete also FGF that 
can, along with the VEGF secreted by platelets and neutrophils, act as an angiogenic factor 
to stimulate endothelial cell proliferation and migration and thus promote vascularization at 
the healing site. While fibroblasts and endothelial cells mostly invade the wound site from 
its bed, keratinocytes at the margin of the wound undergo a transient burst of proliferation 
that will sustain epithelialization over the wound (FIG.3)[Laplante AF et al. 2001] 
 
 Fig. 3. Cells involved on wound healing  
 
Remodeling 
The last step of normal acute wound healing is remodeling, during which the ECM 
components will be modified by the balanced mechanisms of proteolysis and new matrix 
secretion, and during which the wound becomes gradually less vascularized. The initial 
granulation tissue is weak but will gain in strength over time because of remodeling effects 
such as the gradual replacement of immature type III collagen by mature type I collagen. 
The complete maturation of a wound may take months or even years to complete, 
depending on its initial extent and various factors that can affect the healing process 
[[Johnstone and Farley 2005]. Excessive contraction in large wounds can lead to 
contractures, while excess formation of scar tissue will form hypertrophic scars or even, if 
the scar tissue extends into the healthy tissue around the wound, a keloid scar. Wound 
contraction starts taking place around 6 days after injury and can last long after the 
epithelialization phase. The myofibroblast is considered to be the major cell responsible for 
contraction and is easily distinguished from normal fibroblasts by the presence of -smooth 
muscle actin (-SMA). -SMA protein expression is undetectable until day 6 after 
wounding, after subsequently increases gradually for 15 days in the healing process and 
fades after 4 weeks [Brunicardi et al 2005].  
 
3.1 Clinical application 
Today, surgical grafting of split-thickness autologous skin is the mainstay for treatment of 
fullthickness burns and is often used to treat chronic wounds of all kinds. The depth of 
tissue destruction and the need to replace different functions will determine the type of skin 
substitute used:  
a) Rapid replacement of the epidermal layer is important to restore, as fast as 
possible, control over fluid loss, body temperature and protection against bacteria. 
Epidermal or bilayer substitutes that do not provide autologous keratinocytes or 
immunocompatible living tissue, such as cadaveric skin, xenografts and inert 
membranes like silicone, can only provide temporary coverage. They are indicated 
if availability and expected healing speed make them the best or the only option at 
the beginning of the treatment. However, live keratinocytes have to be present to 
achieve permanent wound coverage and restore the epidermal barrier. With 
epidermal substitutes, the presence of autologous living cells is thus necessary for 
proper healing of extensive areas where spontaneous epithelialization is impossible 
or would take too long to complete. Autologous living cells can also be desirable to 
improve the speed and/or quality of the healing in wounds that otherwise would 
be small enough to epithelialize on their own [Macri et Clarke 2009]. 
 
b) In cases where the dermal layer is still at least partially present even after 
debridement, epidermal substitutes that provide living autologous keratinocytes 
can be applied directly on the wound bed and eventually achieve permanent 
wound closure. However, in cases where the dermal layer has been destroyed, the 
application of even the best epidermal substitute is not enough to ensure optimal 
healing.The dermal layer is essential for better elasticity and mechanical resistance, 
the absence of epithelial-mesenchymal communication increases the frequency of 
developing fibrotic conditions [Sawicki et al 2005] and evidence indicates its 
presence allows highly complex ex vivo function of epidermal cells. Thus dermal 
reconstruction should be an essential part of the treatment in cases where none of 
the original dermis is left on the wound bed prepared for grafting. The presence of 
living fibroblasts is not a necessity in dermal substitutes. Such acellular products 
can be sufficient to provide a scaffold that will be repopulated, revascularized and 
remodeled with the patient’s own fibroblasts and endothelial cells. However, the 
presence of fibroblasts in dermal substitutes helps wound healing by providing 
factors of the FGF family, by the secretion of the ECM responsible for its 
mechanical properties and by the structuring effect they have on the formation of 
capillaries during angiogenesis [Mitrani et al 2005]. Dermal substitutes provide a 
crucial component to help repair full-thickness damage, but they do not create a 
barrier effect and need to be covered with an epidermal substitute to that end. 
 
Basically, there are three methods of skin repair and replacement: 
First: autografting.  
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This is a widely used method of treating organ loss. For instance, it is an effective procedure 
for the short-term treatment of full thickness skin loss, especially meshed skin in severely 
burned patients.  Although autologous skin grafts remain the first option in the current 
standard of care for burn patients, there are clinical circumstances where using the donor’s 
own skin might not be appropriate for reasons related to the quantity needed, as in the case 
of massive tissue injury such as extensive burns or because of healing deficiencies that lead 
to chronic wounds. The clinicians then need to turn towards alternative materials that will 
offer appropriate properties for the type and extent of the wound to be treated [Machens et 
al. 2000] 
Second: cadaver skin  
It has offered an alternate pathway to skin replacement for many years. Peter Medawar, in 
his early pioneer work on transplantation immunobiology during the 1930s and 1940s, used 
skin transplants in immunoincompatible animal models and thus outlined very early in the 
history of transplantation medicine that rejection and progressive loss of tissue is a major 
drawback for cadaver skin replacements. In recent decades the consequences of a 
promiscuous multiculture have taught us that additional problems are inherited with this 
type of surgery: hepatitis and the Aids virus are risks which cannot be excluded and make 
cadaver skin transplantation more and more obsolete. The potential of cadaveric allograft 
skin to transmit disease has been recognized as an increasing problem since the 1980s. 
Alternatives to cadaveric skin are represented by native biological substitutes, with or 
without living cells resumed in table 1.[Auger and Lacroix 2009] 
 
Product Commercial name 
Fresh cadaveric skin  
Cryopreserved cadaveric skin AllodermTM 
Glycerolized cadaveric skin  
Fresh xenografts Usually fresh 
porcine disinfected skin 
 
Cryopreserved amniotic 
membrane 
 
AmniograftTM 
Porcine small intestine 
submucosa 
 
OasisTM, 
FortaFlexTM 
 
Porcine skin PermacolTM 
Table 1. commercial natural skin 
 
Third: in vitro reconstructed skin 
This procedure relies on the hypothesis that tissue can, in principle, be cultured in vitro. 
During the several preceding decades, there have been breathtaking achievements in 
medical science in the field of in vitro cell cultivation, tissue engineering and new 
biopharmaceutical as well as recombinant genetic therapies. The skin has been the first 
tissue-engineered organ from the lab bench to the patient [Rheinwald and Green, 1975]. 
Rheinwald and Green took 3T3 cells derived from mouse embryos (the 3T3 cell line 
established by Rheinwald and Green in particular is known as 3T3-J2), irradiated them to 
eliminate their capacity to divide, and co-cultured them with epidermal keratinocytes, 
sufficiently  uppressing the differentiation of the latter to obtain cells with a high 
proliferative capacity (Hiroco, 2007). The greatest merit of cultured epidermis is that it 
enables the grafting of epidermal keratinocytes that have preserved sufficient proliferative 
capacity. 
(Metcalfe) Engineering design specification in skin has relied upon the creation of both 
artificial dermal and epidermal components, which when combined produce a replacement 
of the skin, that can be grafted in place ([Supp and Boyce 2005]. Materials used as artificial 
ECM to date include those derived from naturally occurring materials and those 
manufactured synthetically [MacNeil 2007]. Examples of natural materials include 
polypeptides, GAG’s, fibronectin, collagen, hydroxyapatites, hyaluronan, chitosan and 
alginates. These materials are advantageous in that they have low toxicity and a low chronic 
inflammatory response. Examples of synthetic materials include polyglycolide (PGA), 
polylactide (PLA) and polylactide-coglycolide (PLG), which have been used for sutures and 
meshes [[Metcalfe and Ferguson 2007]. Other examples include polytetrafluoroethylene 
(PTFE), polycaprolactone (PCL) and polyethylene terephthalate (PET). Matrices used 
routinely in therapeutic applications are made from polymers that are often resorbed by or 
degraded in the body. In the early days of tissue engineering, polymers were adapted from 
other surgical uses and over time have been shown to have deficiencies in terms of 
mechanical and degradation properties [Griffith 2002]. A greater challenge arises when 
functionalising these polymers into scaffolds that have defined shapes and a complex, 
porous internal architecture that can direct tissue growth  [Griffith and Schwartz 2006]. 
Current skin constructs that are commercially available are generally based on the following 
techniques: 
a) Epidermis: with only keratinocytes  
The minimum requirement for a viable skin construct is to reestablish a barrier function to 
avoid infection and water loss. The horny layer of the epidermis (the product of terminal 
keratinocyte differentiation) plays this role. As mentioned above, after the breakthroughs of 
Rheinwald and Green in the mid ‘70s, the technology of cultured epithelial autograft (CEA) 
is now available to a large number of hospitals worldwide. In addition, cell culture 
parameters, harvest procedures and usage indications have been strictly defined and CEA 
production is also being performed on an industrial basis.  
Epidermal substitutes 
 
Commercial name Cell source biomaterial 
EpicelTM autologous keratinocytes 
from skin  
petrolatum gauze backing 
EpidexTM autologous keratinocytes 
from hair follicles outer root 
sheath 
silicone membrane 
 
LaserskinTM, autologous keratinocytes esterified laser-perforated 
hyaluronic acid matrix 
 
BioSeed-STM Autologous oral mucosal 
cells 
fibrin matrix 
MyskinTM autologous keratinocytes specially treated silicone 
sheet 
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This is a widely used method of treating organ loss. For instance, it is an effective procedure 
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CellSprayTM autologous keratinocytes suspension for spray 
CryoskinTM Cryopreserved (viable cells) 
confluent allogeneic 
keratinocytes 
gel-like proprietary 
chemical surface 
 
The greatest merit of cultured epidermis is that it enables the grafting of epidermal 
keratinocytes that have preserved sufficient proliferative capacity. Whatever the 
circumstances, patients in whom epidermal damage has occurred all ultimately require an 
epidermis composed of epidermal keratinocytes. The only hope for patients with 
widespread epidermal damage, such as whole-body burns, is the localized capacity of 
surviving epidermal keratinocytes to divide and proliferate, and their treatment requires an 
extremely long period of time. Although autologous grafting of skin from other areas of the 
body is the surgical norm, the amount of skin that can be harvested is limited, and 
furthermore, new epidermal damage is created at the donor site. On the other hand, 
cultured epidermis is very thin, and its use is problematic in cases of deep skin damage such 
as for patients in whom the dermis has been completely destroyed. For this reason, other 
methods must be used in advance to create dermal tissue that can offer a favorable base for 
grafting. [Hichiro 2007] 
 Fig. 4. Principal steps for in vitro epidermal skin reconstruction 
 
Technique: 
Keratinocytes are isolated from full-thickness skin biopsies (3×1 cm) (step1) obtained from 
healthy patients with ages ranging from 35 to 45 years. Keratinocytes are isolated and 
cultured according to a modified version of the Rheinwald and Green protocol. Briefly, 
dermal specimens are immersed in DMEM supplemented with 20% FBS and minced 
(step2).The small fragments obtained, are digested in 0.6 U/ml dispase II (Boehringer 
Mannheim) at 37° C for 1 h, at this time a manual separation between dermis and epidermis 
is performed (step2). The epidermis will be treated with trypsin ± EDTA (0.05%, 0.02 mM) 
solution (Seromed. Biochrom KG) for 10 min and the cells collected after a centrifugation 
and seeded in flask treated with a special keratinocytes attachment factors or in a feeder 
layer of 3T3 (step3). 
For 3D coltures, keratinocytes are plated in secondary cultures at a density of 2 × 104 
cells/cm2 onto the biomaterials (e.g. hyaluronic acid: LaserSkin membrane) in the presence 
of a feeder layer of nonproliferating 3T3 mouse fibroblasts (step4). 
  
b) Dermis: presences of fibroblasts.  
Fibroblasts are mesenchymal cells that can be readily cultured in the laboratory and play a 
significant role in epithelial–mesenchymal interactions, secreting various growth factors and 
cytokines that have a direct effect on epidermal proliferation, differentiation and formation 
of extracellular matrix. They have been incorporated into various tissue-engineered 
products such as Dermagraft_ (Advanced BioHealing, La Jolla, CA, U.S.A.) and Apligraf_ 
(Novartis, Basel, Switzerland) and used for a variety of clinical applications, including the 
treatment of burns, chronic venous ulcers and several other clinical applications in 
dermatology and plastic surgery. Fibroblasts are a heterogeneous population of cells found 
in numerous tissues and are of mesenchymal origin. Fibroblasts from different anatomical 
sites all have similar morphology but DNA-microarray studies have demonstrated that 
fibroblasts in different anatomical sites have their own gene-expression profile and 
characteristic phenotypes, synthesizing extracellular matrix (ECM) proteins and cytokines in 
a site-specific manner. Dermal fibroblasts have numerous functions, not only in 
synthesizing and depositing ECM components, but also proliferation and migration in 
response to chemotactic, mitogenic and modulatory cytokines, and also autocrine and 
paracrine interactions [Wong et al 2007]. 
Fibroblasts used in tissue engineering may be allogenic or autologous. In contrast to 
allogenic cells, autologous fibroblasts carry no risks of rejection or risk of cross-infection. 
Cultured dermis using fibroblasts falls within this field, and has been produced with a 
number of materials. As the basic element, collagen or other biodegradable material has 
been used as a scaffold to create a tissue consisting of dermis-derived fibroblasts. Treatment 
using cultured dermis makes use of the wound-healing effects brought about by the 
physiologically active substances produced by fiobroblasts. Normally, the creation of 
granulation tissue mediated by localized inflammation is observed as a biological reaction at 
the site of skin loss. The reconstruction of connective tissue increases with time, mainly by 
the action of fibroblasts from the surrounding area, as does capillary regeneration. Cultured 
dermis, by enabling cultured fibroblasts to produce physiologically active substances that 
are important in the reconstruction of connective tissue, promotes favorable wound 
treatment. The intended effect of cultured dermis is the promotion of wound treatment by 
means of the physiologically active substances produced by fibroblasts contained within the 
culture. As results this treatment is characterized by the lack of any significant difference in 
outcome whether the fibroblasts used are autologous or allogeneic cells. In emergency use 
for burns, for example, allogeneic cultured dermis made in advance from allogeneic cells is 
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of high clinical utility. It will be necessary to solve the variety of concerns related to the use 
of living cells, as well as to demonstrate this method’s clear therapeutic advantages over the 
use of pharmaceuticals alone through numerous examples of clinical application. [Hichiro 
2007] 
 
Dermal substitutes 
Commercial name Cell source biomaterial 
DermagraftTM Cryopreserved (viable cells) 
allogeneic fibroblast 
derived dermal matrix 
Hyalograft 3DTM autologous fibroblasts Esterified hyaluronic acid 
matrix 
AllodermTM  Acellular (freeze-dried) 
allogeneic dermis 
OasisTM  porcine small intestine 
submucosa 
EZ-DermTM  Aldehyde-crosslinked 
porcine dermal collagen 
RepliformTM  Acellular human dermal 
allograft 
CymetraTM  Micronized particulate 
acellular cadaveric dermal 
matrix 
FortaFlexTM  porcine small intestine 
submucosa 
BiobraneTM  Porcine collagen 
chemically bound to 
silicone/nylon membrane 
MatridermTM  Acellular scaffold made 
with bovine collagen types 
I, III, V and elastin 
 
Technique: 
Human dermal fibroblasts are prepared according to a modified version of the Rheinwald & 
Green protocol. After epithelial sheet dispase removal, dermis was cut into small pieces (2–3 
mm2) and fibroblasts were isolated by sequential trypsin (0,05%)  and collagenase type I 
digestion. Cells isolated are then cultured with DMEM medium supplemented with 10% 
Foetal Bovine Serum (FBS). At confluence fibroblasts are harvested and seeded at a density 
of 3 × 105/cm2 on squares of biomaterials (i.e. hyaluronan non woven meshes) (1.5 × 1.5 cm) 
in the above-mentioned medium containing sodium ascorbate (50 mg/mL) (step 5). The 
nonwoven squares could be fixed on culture plates either by means of stainless steel rings or 
through a fibrin clot. 
 
  
c) Co-coltures of fibroblasts and keratinocytes (Bilayer substitutes). 
After these first attempts, given that fibroblasts are the main constituent of the dermis and 
are normally used to grow keratinocytes, the concept of a co-culture was introduced in 
order to produce in vitro a composite skin replacement composed of an epithelial layer 
overlaid onto a dermal substitute. The presence of fibroblasts within the grafted region is 
thus a major advantage. Several lines of research are being pursued to define the best 
conditions of use. These include studies of allogenic fibroblast persistence in humans. Such 
fibroblasts persist in animals, but in humans, even if allogenic fibroblasts give similar results 
to autologous fibroblasts, their ultimate fate is unknown. Definition of fibroblast 
populations within the dermis has been undertaken. There is clear evidence that, depending 
on the anatomical region or the depth within the dermis, fibroblasts can be distinguished on 
the basis of functional criteria. It would be useful to have markers to select those cells that 
would be most efficient within dermal substitutes. At present despite active research in this 
field there is still no commercially available fibroblast marker. Lastly, the possibility of using 
mesenchymal stem cells collected from bone marrow or peripheral blood, which seem to 
participate in wound healing, is being evaluated. In addition to skin substitutes for 
permanent skin replacement, other applications can help to rapidly cover patients' wounds 
(despite eventual rejection of allogenic cells) or to accelerate healing. It is already known 
that allogenic epidermal cell cultures promote external ulcer healing, [Zavan and 
Abatangelo 2004] probably by secreting factors (matrix metalloproteinases, growth factors, 
etc.) that promote wound cleansing and stimulate the activity of cells present at the wound 
site. At the end, the importance of the scaffold for a dermal-like tissue must be stressed too. 
In fact, the design of a dermal-like tissue critically depends on the use of an ideal scaffold 
which must allow the dermis to develop into a three-dimensional architecture. One of the 
most important features of the scaffold is its porosity, which has to fit the neo-vessel 
ingrowth from the host tissue (angiogenesis) during the wound healing process. In addition, 
the biomaterial should be fully biocompatible and totally degradable being substituted by a 
full functional ECM in the long term. Finally, the material should be resistant to mechanical 
forces and easy to apply on the wound area. 
The following guidelines emerged from the clinical experience: 
 The homogeneity of the cultured epidermal sheet is crucial for a good cosmetic 
result. 
 One-step grafting of a cocultured dermis and epidermis is not yet satisfactory, and 
would be too lengthy for emergency use (e.g., burns). 
 Preliminary grafting of a collagen matrix is hemostatic, reduces pain, and prepares 
the graft bed. 
 Most importantly, the presence of living fibroblasts speeds up the reappearance of 
a functional neodermis (less than 1 year instead of 3 to 5years when the graft bed is 
prepared only with cryopreserved cadaver skin). 
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Bilayer substitutes 
Commercial name Cell source biomaterial 
OrCelTM Allogeneic keratinocytes 
seeded over dermal scaffold 
containing allogeneic 
fibroblasts 
bovine collagen 
sponge 
ApligrafTM Allogeneic keratinocytes 
seeded over dermal scaffold 
containing allogeneic 
fibroblasts 
bovine collagen 
sponge 
TissueTechTM autograft 
system 
 
Combination of Hyalograft 
3DTM and LaserskinTM 
 
PermaDermTM Autologous keratinocytes 
seeded onto dermal 
substitute made with 
autologous fibroblasts in 
bovine collagen matrix 
 
bovine collagen matrix 
 
IntegraTM  Temporary silicone 
epidermal substitute over 
dermal scaffold 
made of collagen and 
chondroitin-6 sulfate 
 
 
The success of a skin equivalent graft–take requires the viability of fibroblasts contained 
within and the keratinocytes 
adhering to the surface. When either keratinocytes or fibroblasts are directly introduced into 
a freshly made excisional 
wound, there is rapid necrosis of these transferred cells. When components are put together 
in vitro and transferred 
to an excisional wound site in vivo, the skin equivalent graft has optimal skinlike qualities. 
Technique: 
At confluence (10–12 days), pieces of membranes (1.5 × 1.5 cm) previously seed with 
keratinocytes (step 4) are laid down and fixed to the nonwoven meshes on which dermal 
fibroblasts had been grown for 15 days (step 5). The fibroblast–keratinocyte composite 
cultures were laid down carefully on sterile stainless steel grids and then cultivated for 15 
days at the air–liquid interface (step 6). 
 
 
4. Conclusion 
The many studies conducted so far reveal that Tissue Engineering of the skin is only at the 
beginning of its use in human applications. Burns patients were the first targets for such 
tissue substitutes, then chronic diseases, such as venous ulcers, have followed. The more 
experience is gained from the surgeon, the more feedback for the basic scientist to improve 
the product and to broaden clinical indications. Nowadays, progress in cell culture and 
biomedical material technologies have added two important spare parts: epidermis and 
dermis to the surgeon’s toolbox which can be reconstituted in the laboratory from small 
biopsies of the same recipient. Other parts will follow in a few years, with the final aim to 
generate a full transplantable replica of the skin with adnexa and vasculature.  
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Bilayer substitutes 
Commercial name Cell source biomaterial 
OrCelTM Allogeneic keratinocytes 
seeded over dermal scaffold 
containing allogeneic 
fibroblasts 
bovine collagen 
sponge 
ApligrafTM Allogeneic keratinocytes 
seeded over dermal scaffold 
containing allogeneic 
fibroblasts 
bovine collagen 
sponge 
TissueTechTM autograft 
system 
 
Combination of Hyalograft 
3DTM and LaserskinTM 
 
PermaDermTM Autologous keratinocytes 
seeded onto dermal 
substitute made with 
autologous fibroblasts in 
bovine collagen matrix 
 
bovine collagen matrix 
 
IntegraTM  Temporary silicone 
epidermal substitute over 
dermal scaffold 
made of collagen and 
chondroitin-6 sulfate 
 
 
The success of a skin equivalent graft–take requires the viability of fibroblasts contained 
within and the keratinocytes 
adhering to the surface. When either keratinocytes or fibroblasts are directly introduced into 
a freshly made excisional 
wound, there is rapid necrosis of these transferred cells. When components are put together 
in vitro and transferred 
to an excisional wound site in vivo, the skin equivalent graft has optimal skinlike qualities. 
Technique: 
At confluence (10–12 days), pieces of membranes (1.5 × 1.5 cm) previously seed with 
keratinocytes (step 4) are laid down and fixed to the nonwoven meshes on which dermal 
fibroblasts had been grown for 15 days (step 5). The fibroblast–keratinocyte composite 
cultures were laid down carefully on sterile stainless steel grids and then cultivated for 15 
days at the air–liquid interface (step 6). 
 
 
4. Conclusion 
The many studies conducted so far reveal that Tissue Engineering of the skin is only at the 
beginning of its use in human applications. Burns patients were the first targets for such 
tissue substitutes, then chronic diseases, such as venous ulcers, have followed. The more 
experience is gained from the surgeon, the more feedback for the basic scientist to improve 
the product and to broaden clinical indications. Nowadays, progress in cell culture and 
biomedical material technologies have added two important spare parts: epidermis and 
dermis to the surgeon’s toolbox which can be reconstituted in the laboratory from small 
biopsies of the same recipient. Other parts will follow in a few years, with the final aim to 
generate a full transplantable replica of the skin with adnexa and vasculature.  
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